Facebook
Instagram
Linkedin
Youtube
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Search
BioStock
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Home
Search
cereno
-
search results
If you're not happy with the results, please do another search
Cereno comments on EU orphan designation for CS1
9 September, 2024
Cereno’s CEO: “very excited for topline readout!”
29 August, 2024
Cereno’s CEO comments on progress with CS1 and CS014
8 July, 2024
Cereno’s CEO: “CS014 adds potential for cardiovascular disease patients”
20 June, 2024
Cereno’s new CMO and Head of R&D comments on progress with...
12 March, 2024
Cereno’s CEO on being granted “Compassionate Use”
6 February, 2024
All sessions from BioStock Life Science Fall Summit 2023
30 October, 2023
Video from day 1 of BioStock Life Science Fall Summit 2023
26 October, 2023
Cereno reports positive data from patient case study
29 June, 2023
Cereno listed on Nasdaq First North Growth Market
15 June, 2023
The BioStock Life Science Spring Summit 2023 goes live today
30 May, 2023
Cereno builds momentum for major clinical milestones
19 May, 2023
Cereno’s CEO on current development and move to First North
16 May, 2023
Cereno signs licensing deal with University of Michigan
5 April, 2023
Cereno Scientific’s CBO about his new role
7 March, 2023
Cereno launches Insights Series videos
14 February, 2023
Amgen targets rare diseases with acquisition
15 December, 2022
The value of patent protection in life science
14 December, 2022
Cereno’s CIPO comments on strong IPR position
5 December, 2022
Cereno Scientific raises 61 million SEK in warrant exercise
11 October, 2022
BioStock Investor Meeting: Interview with Cereno Scientific
26 September, 2022
BioStock Investor Meeting: Cereno Scientific presents
19 September, 2022
Cereno reveals promising data for preclinical CVD candidate
5 September, 2022
BioStock Investor Meeting, September 14
15 August, 2022
First patient enrolled in Cereno Scientific’s phase II study
11 July, 2022
Watch day 2 of the BioStock Life Science Spring Summit
9 June, 2022
The BioStock Life Science Spring Summit starts now
8 June, 2022
Cereno Scientific’s CS014 attracts interest from medical community
18 May, 2022
Cereno Scientific to present promising CS585 data
11 May, 2022
Cereno Scientific nominates two new preclinical drug candidates
6 May, 2022
BioStock Life Science Spring Summit, June 8-9, 2022
26 March, 2022
Cereno Scientific strengthens IPR in Europe
4 March, 2022
Cereno Scientific strengthens R&D organisation
25 February, 2022
BioStock Studio: Cereno Scientific releases report and looks ahead
10 February, 2022
Cereno Scientific reaches milestone with CS014
1 February, 2022
Cereno Scientific solidifies CS1 patent protection in Japan
25 January, 2022
Cereno Scientific eyes an eventful 2022
12 January, 2022
Cereno Scientific expands patent rights for CS1
20 December, 2021
Cereno Scientific brings CVD expertise to CVCT Forum
2 December, 2021
BioStock Studio: Cereno Scientific’s CEO comments on the third quarter
17 November, 2021
Join us for the BioStock Life Science Summit on October 20...
20 October, 2021
Cereno Scientific raises 95.3 million SEK
5 October, 2021
Cereno Scientific receives IND acceptance for phase II start
21 September, 2021
BioStock Studio: Cereno Scientific’s CEO about the milestone in the CS1...
20 September, 2021
Cereno Scientific expands patent portfolio
9 September, 2021
BioStock Studio: Cereno’s CEO is looking forward to trial start
26 August, 2021
Cereno Scientific enters collaboration with Abbott
19 August, 2021
A trio of cardiovascular heavyweights join Cereno’s Scientific Advisory Board
8 July, 2021
Approved study and prestigious meetings in fibrosis put Cereno Scientific in...
6 July, 2021
Cereno Scientific strengthens its pipeline for the second time this year
6 July, 2021
Cereno Scientific delays start of phase II trial
5 July, 2021
Cereno Scientific adds a clinical expert to its ODD track
5 July, 2021
Cereno Scientific announces US subsidiary in Cambridge, Boston, MA
5 July, 2021
Cereno Scientific is shifting gears
3 July, 2021
Cereno Scientific builds high-profile network in CVD
2 July, 2021
Cereno Scientific granted IPR protection in Australia
30 June, 2021
Cereno Scientific drives a paradigm shift in CVD
29 June, 2021
Status Report Cereno Scientific – Expanded potential in cardiovascular disease
14 June, 2021
Innovation in focus at BioStock Life Science Spring Summit 2021
25 May, 2021
BioStock Studio: Cereno Scientific’s CEO about expanded portfolio and upcoming phase...
24 May, 2021
1
2
Page 1 of 2
